In this work, we present and discuss a comprehensive set of both newly and previously synthesized compounds belonging to 5 distinct molecular classes of linear aromatic N-polycyclic systems that efficiently inhibits bovine viral diarrhea virus (BVDV) infection. A coupled in silico/in vitro investigation was employed to formulate a molecular rationale explaining the notable affinity of all molecules to BVDV RNA dependent RNA polymerase (RdRp) NS5B. We initially developed a three-dimensional common-feature pharmacophore model according to which two hydrogen bond acceptors and one hydrophobic aromatic feature are shared by all molecular series in binding the viral polymerase. The pharmacophoric information was used to retrieve a putative binding site on the surface of the BVDV RdRp and to guide compound docking within the protein binding site. The affinity of all compounds towards the enzyme was scored via molecular dynamics-based simulations, showing high correlation with in vitro EC 50 data. The determination of the interaction spectra of the protein residues involved in inhibitor binding highlighted amino acids R295 and Y674 as the two fundamental H-bond donors, while two hydrophobic cavities HC1 (residues A221, I261, I287, and Y289) and HC2 (residues V216, Y303, V306, K307, P408, and A412) fulfill the third pharmacophoric requirement. Three RdRp (K263, R295 and Y674) residues critical for drug binding were selected and mutagenized, both in silico and in vitro, into alanine, and the affinity of a set of selected compounds towards the mutant RdRp isoforms was determined accordingly. The agreement between predicted and experimental data confirmed the proposed common molecular rationale shared by molecules characterized by different chemical scaffolds in binding to the BVDV RdRp, ultimately yielding compound 6b (EC 50 ¼ 0.3 mM; IC 50 ¼ 0.48 mM) as a new, potent inhibitor of this Pestivirus.
Introduction
DNA and RNA viruses represent a major cause of disease in humans and animals. Some of them, notably the Ebola and, previously, the H1N1 viruses expressed their ability to create a pandemic scenario across globe, highlighting our unpreparedness to face infections caused by neglected pathogens that can easily spread worldwide. In this panorama, our multiannual program of antiviral research has focused on the design and synthesis of a wide series of small molecules endowed with antiviral activity. Various lead compounds emerged during the years, mainly active against representative viruses of Flaviviridae family.
The Flaviviridae is a large family of related positive-strand RNA viruses (ssRNA þ ) that consists of three genera: Flavivirus, Pestivirus and Hepacivirus. Several globally important human and animal pathogens [1] are comprised within this group. The family members are genetically diverse but share similarities in genome organization, mechanisms of gene expression, and replication strategies [2] . The Flavivirus genus currently contains 73 viruses classified as 53 species [3] divided into four groups: the tick-borne Flaviviruses, the mosquito-borne Flaviviruses, the not-known-vector Flaviviruses, and the non-classified Flaviviruses. A number of the arthropod-borne Flaviviruses cause disease in humans. Particularly, Dengue Fever (DFV), Yellow Fever (YFV), West Nile (WN), and Japanese Encephalitis (JE) viruses cause acute febrile illness, encephalitis, and hemorrhagic fevers, against which effective vaccines or established drug treatments for related disease prevention and cure are still lacking. Attenuated YFV-based vaccines represent a noteworthy exception in this setting, although, despite their effectiveness, they sometimes shows toxic side effects that can be fatal [4] , and their utilization is incomplete in many areas [5] .
The Pestivirus genus includes animal pathogens of major economic impact for the livestock industry, such as Swine Fever virus (SFV), Border Disease virus (BDV), and Bovine Viral Diarrhea virus (BVDV) [6] . Particularly, BVDV establish a persistent infection in cattle that remain viremic throughout life and often succumb to fatal mucosal disease [7] . Furthermore, BVDV shows the ability to cross the placenta of susceptible animals causing a variety of fetal infections [8] . In the United States alone, a recent study revealed that the cost of exposing calves to BVDV in the feed-yard was $67.49/head. The vast majority of this amount, $58.83, was due to the loss in performance, primarily decreased efficiency. The remainder ($8.66) reflected an increase in mortality. The bottom line of this report is that, while few in number, persistently infected calves can have an economically devastating effect in feedlot cattle [9] . BVDV represents the prototypical Pestivirus virus and therefore is the best-characterized member of this group. Because of the genome organization, translation, replication strategy, and protein functions of Pestiviruses, BVDV is more closely related to Human Hepatitis C (HCV) virus than any of the classical Flaviviruses. As such, it has been widely adopted as a surrogate model for anti-HCV drug design and development [10, 11] . Lastly, BVDV is easily cultured in vitro, where it undergoes a complete replication cycle, and molecular clones are available for genetic studies.
The Hepacivirus genus features only HCV, the major cause of human hepatitis, globally [12] . The most recent World Health Organization (WHO) report estimates that 130e150 million people globally have chronic hepatitis C infection [13] .
At the moment, patients with severe cases of Flavivirus infections are treated only by supportive care, which includes intravenous fluids, hospitalization, respiratory support, and prevention of secondary infections [14] . In fact, despite worldwide extensive research and public health concern associated with Flavivirus diseases, no specific/routine treatment is available today to combat any Flavivirus infections, the sole exception being constituted by new drugs (e.g., simeprevir and sofosbuvir) currently in clinical trials for hepatitis C [15, 16] . Consequently, there is an urgent need for new lead compounds that efficiently target distinct stages of the viral replication cycle in a virus-specific way.
In this context, and in the framework of a long-lasting antiviral research program, our group designed and synthesized a series of new angular and linear N-polycyclic systems against representative ssRNA þ viruses. Small molecules inhibitors of BVDV has been reported in the literature with various scaffolds [17] .
We recently reported a bicyclic system such as (E)-2-(1-(2-(2,4-dimethoxyphenyl)-1H-benzo[d]imidazol-5-yl)ethylidene)hydrazine-1-carbothioamide (227G, Fig. 1 ) that inhibits, in cell-based assays, both BVDV and HCV replication in the low micromolar range (EC 50 values of 0.80 and 1.11 mM, respectively) [18] .
The molecular target was identified in the viral RNA dependent RNA polymerase (RdRp) [19] and doseeresponse curves indicate that 227G potently inhibits (IC 50 ¼ 0.0020 ± 0.0004 mM) the BVDV RdRp activity [20] . In an attempt to widen the knowledge on the anti BVDV activity of nitrogen-containing heterocyclic compounds we complicate the bicyclic system and we synthesized a series of [4, 7] phenantroline derivatives [21] (Fig. 2) . At first, we demonstrated that some [4, 7] phenantroline derivatives were fairly active against BVDV in vitro, compound A1 being particularly promising against both BVDV and HCV (Fig. 2) . Next, in silico experiments on the putative final target, the HCV RNA-dependent RNA-polymerase (RdRp) NS5B, contributed to develop a molecular-based rationale for the structureeactivity relationship (SAR) for these compounds [21] . The target enzyme was identified in the light of some similarities between a number of our active compounds and the nonnucleoside inhibitor of HCV NS5B ((2s)-2-[(2,4-dichloro-benzoyl)-(3-trifluoromethyl-benzyl)-amino]-3-phenyl-propionic acid), hereafter named Shire A [22] .
Unfortunately, the most potent angular derivatives turned out to be non-selective inhibitors of BVDV. Compound A1, in fact, resulted active against non only BVDV but also against CVB-2 and Sb-1 (EC 50 ¼ 5 and 17 mM, respectively). With the aim of improving both their potency and selectivity towards BVDV, we next conceived and synthesized three new classes of linear aromatic Ntricyclic compounds derived from the expansion of the quinoline nucleus with 1,2,3-triazole, imidazole or pyrazine (Fig. 3) [23] . Thus, triazolo [4,5-g] quinoline (B), imidazo [4,5- g]quinoline (C), and pyrido[2,3-g]quinoxaline derivatives (D) were tested in cell-based assays for both cytotoxicity and antiviral activity against representative members of several virus families, and found endowed with promising antiviral activity and selectivity index against several pathogenic RNA viruses [23] .
Interestingly, while selective anti-BVDV activity was reported for all three classes of compounds in Fig. 3 , derivatives endowed with substantial anti-BVDV activity were more numerous among imidazoquinolines and pyridoquinoxalines than among triazoloquinolines. Nevertheless, each class contained at least one potent and selective molecule. On this basis, selected leads from these series were then evaluated for anti-HCV activity in a replicon system and tested in enzyme assays for activity against the RdRps of BVDV and HCV. 4-Chloro-2-(4-nitrophenyl)-3H-imidazo [4,5-g] quinoline (C2, Fig. 4 ) thus emerged as the most potent and selective compound against BVDV (EC 50 ¼ 1.2 mM, CC 50 > 100 mM) [32] . It also proved to be active, although only moderately selective, against HCV. These results suggested that, although with different efficiency, compound (C2) (Fig. 4) targets both viral RdRps. Consequently, to broad our knowledge concerning the SAR of imidazo [4,5-g] quinolines, the chemical structure of C2 was simplified via the elimination of the central ring or the opening of the imidazole ring, leading to various imidazopyridines (E) and N-benzylidenequinolinamines (F), respectively (Fig. 4) . Remarkably, just a few imidazopyridine derivatives resulted active against BVDV, while all N-benzylidenequinolinamines maintained their antiviral behavior. Particularly, compounds F1 and F2 showed EC 50 values of the same order of magnitude of the reference drug 2 0 -C-methyl-guanosine (1.1 mM) [24] -as shown in Fig. 4 .
The selective anti-BVDV activity of pyridoquinoxaline-based compounds (D) [23] was also further investigated by synthesizing further derivatives, among which the thienyl derivative (D1) showed selectivity, good potency and an interesting balance between activity and cytotoxicity (Fig. 5) .
Furthermore, the derivatives bearing different substituents on the N atom at position 1 or the O atom at position 2 were tested in cell-based assays for cytotoxicity and antiviral activity. The 5-chloro-2-methoxy-3-(thiophen-2-yl)pyrido[2,3-g]quinoxaline D2, totally devoid of cytotoxicity, emerged for its selective and potent antiviral activity against BVDV (EC 50 ¼ 1.3 mM, Fig. 5 ). Molecular modeling studies confirmed the BVDV RdRp as the target enzyme for these compounds and allowed the identification of important molecular determinants for their NS5B inhibition [25] .
To expand the SAR investigation on the above linear N-tricyclic systems, in the present paper we initially designed and synthesized new imidazo [4,5-g] quinolines derived by further development of the basic compound 2-phenyl-3H-imidazo [4,5-g] quinoline (C1) (EC50 ¼ 4 mM, CC50 > 100 mM) [32] . To this purpose, we modulated substituents at positions R 1 , R 2 , and/or R 3 , or replaced the phenyl ring with a heterocyclic moiety, as illustrated in Fig. 6 . Specifically, substituents were chosen with the aim of evaluating the influence of electron donating groups (EDGs) or electron withdrawing groups (EWGs) on the phenyl group (R 3 in Fig. 6 ), of the Cl atom at position R 1 , and/or general steric hindrance of substituents in R 2 on the antiviral activity of the resulting molecules.
Thus, we synthesized compounds bearing either chlorine or hydrogen at position R 1 to quantify the specific contribution of the halogen to the compound affinity for the binding site of the BVDV NS5B. In addition, a large moiety such as methyl cyclohexyl was inserted in R 2 to test the tolerance of the viral polymerase binding pocket towards substituent bulkiness. In combination with the two modifications mentioned above, EDGs or EWGs were inserted at the 4 0 position or at the 2 0 and 4' positions of the phenyl ring (R 3 in Fig. 6 ). Lastly, we synthesized and assayed a furan(3)-yl derivative since no compound bearing a heterocyclic moiety at position 2 was previously reported. All modifications are indicated in details in Scheme 1.
In the light of the encouraging results obtained, we next proceeded by performing a parallel in silico/in vitro analysis of the best compounds of all previous (BeF) [23, 24] and present series and determined the common molecular determinants leading to their successful BVDV RdRp inhibition.
Chemistry
The synthetic route to obtain the designed 3H-imidazo [4,5-g] quinoline derivatives (2-5a, 6e11b, 12e13c, and 14b) is shown in Scheme 1. The diamines 1a-c react with appropriate bisulphite compounds (15 and 17) in refluxed ethanol or in dimethylformammide (DMF) at 130 C for 2e12 h, to give the corresponding 3H-imidazo[4,5-g]quinolines (2-5a, 6e10b, 12e13c, and 14b) in good yield (54e90%), with the exception of 13c (25%). Compound 4-(4-chloro-3H-imidazo[4,5-g]quinolin-2-yl)benzenesulfonamide (11b) was in turn prepared by condensation of the diaminoquinoline 1b with 4-sulfamoylbenzoic (16) and polyphosphoric acid for 4 h at 200 C (25% yield). 6,7-Diaminoquinolines 1a-c intermediates were prepared following the procedure previously described [23, 26] . Bisulphite compounds (15 and 17) , were obtained by reacting the aldehydes with Na 2 S 2 O 5 in hydroalcoholic solution [23] . Aldehydes and inorganic reagents were commercially available.
Results and discussion
As discussed above, the original hypothesis motivating the current work proposed that specific substituents at different positions of the scaffold of the lead compound C1 (Fig. 6 ) would be selective and effective inhibitors of the BVDV RdRp. To investigate this proposition, compounds 2-5a, 6e11b, 12e13c, and 14b were synthesized and evaluated for activity and selectivity against BVDV and other ssRNAþ, ssRNA-, dsRNA and DNA viruses. Data from these experiments are presented in Table 1 and Table S1 , respectively.
From the results shown in Table 1 it is apparent that all compounds, with the singular exception of 11b, were significantly active, with EC 50 ranging between 0.3 and 7 mM along with low cytotoxicity (CC 50 > 100 mM, except for compounds 12c and 13c, for which CC 50 ¼ 20 and 33 mM, respectively). The selectivity index (S.I.), which is a parameter of preferential antiviral activity of a compound in relation to its cytotoxicity (CC 50 /EC 50 ), of all new compounds is also tabulated in Table 1 . As can be seen, the SI index values of the title compounds were substantially better than those of the positive controls, 2 0 -C-methyl-guanosine (S.I. ¼ 9.1) and of the gold-standard reference ribavirin, for which S.I. ¼ 3.8.
Preliminary SARs shows that the presence of a chlorine substituent on the scaffold of compound C1 (R 1 in Fig. 6 (Table S1 ), we can reasonable identify these new quinolone derivatives as selective and potent anti-BVDV agents.
The occurrence of a bulky substituent in R 2 does not result in an appreciable effect on the activity of the relevant compound 13c with respect to the analogous, unsubstituted molecule C2 (EC 50 ¼ 5.0 m and 1.2 mM, respectively), implying that the target BVDV RdRp can accommodate a large group at that position with Finally, compound 14b, featuring the replacement of the phenyl ring on the scaffold of C1 with a heterocyclic moiety (i.e., furane), showed better antiviral activity (EC 50 ¼ 2.0 mM) than the C1 derivative, preserving at the same time its non-toxic character (CC 50 > 100 mM). Ordinarily, the development of a pharmacophore model aims at creating a powerful tool for the design of new and possibly more potent molecules with respect to a specific target. In this work, however, the common feature pharmacophore approach was exploited to identify the molecular requirements shared by all series of compounds (i.e., previously synthesized B-F series [23, 24] , and newly synthesized compounds 2-5a, 6e11b, 12e13c, and 14b) in determining their inhibitory activity against the BVDV RdRp. Accordingly, a selection of 31 compounds among the entire sets were selected, along with their experimentally BVDV EC 50 values, as the training set for the development of the corresponding threedimensional (3D) pharmacophore model (Fig. S1 ).
The calculated best-fit values ranked Hypo1, which consists of two Hydrogen Bond Acceptor features (HBA) and one Hydrophobic Aromatic feature (HY_AR) (Fig. 7A) , as the best model. Accordingly, the most active compounds of training set belonging to the 4 different scaffolds considered in this paper were mapped onto Hypo1, as shown in Fig 7BeF. In the successive step, taking advantage of (i) the ligand-binding pharmacophoric requirements determined above, and (ii) the binding mode of compound D2 onto the BVDV RdRp described in our previous work [25] , we docked and scored the free energy of binding DG bind for compounds B1, 6b, E2, and F2 towards the viral target protein, using these 4 additional compounds (together with D2) as proofs-of-principle.
Briefly, for compound D2 we already located a putative binding pocket located between the BVDV RdRp fingers domains 1 and 2 Scheme 1. Selected chemical modifications of lead compound C1 and synthetic pathways leading to the compounds 2-5a, 6e11b, 12e13c, and 14b. (residues 139e313 and 351e410, respectively) [25] . By applying a consolidated molecular dynamic (MD) computational recipe [27, 28] , some specific interactions between the pyridoquinoxaline derivative D2 and the critical RdRp binding site residues were identified. In details, the aromatic portions of D2 are encased in two receptor cavities comprising residues A221, I261, I287, Y289 and V216, Y303, V306, K307, P408 and A412, respectively. Moreover, two stable hydrogen bonds (HBs) were detected between the Npyrido and the quinoxaline nitrogen atom of D2 and the donor atoms of the side chains of R295 and Y674 of the BVDV RdRp, respectively (Fig. 8) . For the record, the thiophene ring of D2 was involved -through its sulfur atom -in a further HB with S411; however, since the strength of this additional HB was weaker compared to the other two polar interactions [25] , it was classified as a secondary requirement for binding optimization.
Therefore, a thorough search for a residue sequence satisfying the 3D pharmacophoric requirements described above was performed and successfully retrieved in this specific protein region. As clearly shown in Fig. 8 , the three features identified by our 3D pharmacophore model find the corresponding counterparts in the binding mode interactions collected by the MD procedure.
The image is a zoomed view of the polymerase binding site. The ligand is portrayed in atom-colored sticks-and-balls (gray, C; blue, N; green, Cl; yellow, S), while the secondary structure of the protein is shown as a gray transparent ribbon. The residues satisfying the 3D pharmacophoric requirements in the interaction with D2 are evidenced as green (HBA) and cyan (HY_AR) sticks and labeled. The cyan area represents the hydrophobic cavity in the protein binding site which encases the heterocyclic moiety of the compound (see Fig. 6 ). Dark gray labeled residues in sticks within the dark gray area represent the second protein hydrophobic cavity next to the pyridoquinoxaline ring of D2. Hydrogen atoms, water molecules, ions and counterions are omitted for clarity.
In the light of these encouraging results, following the same procedure, compounds B1, 6b, E2, and F2 were also docked and scored for affinity towards the binding site of the BVDV RdRp. Pleasingly, for each compound a solution was found in the corresponding set of docked ligand conformations that best reproduced the key 3D pharmacophore requirements, as shown in Fig. 9 . Each resulting receptor/ligand complex was then relaxed by energy minimization, followed by MD simulations. Finally, the relevant values of the free energy of binding DG bind between all compounds and the polymerase were evaluated by applying the molecular mechanics/PoissonÀBoltzmann surface area (MM/PBSA) computational ansatz (see Computational Details), as listed in Table 2 .
The image is a zoomed view of the polymerase binding site. Ligands are portrayed in atom-colored sticks-and-balls (gray, C; blue, N; green, Cl; yellow, S), while the secondary structure of the protein is shown as a gray transparent ribbon. The residues satisfying the 3D pharmacophoric requirements in the interaction with D2 are evidenced as green (HBA) and cyan (HY_AR) sticks and labeled. The cyan area represents the hydrophobic cavity in the protein binding site which encases the phenyl/heterocyclic moiety of the compounds (see Fig. 6 ). Dark gray labeled residues in sticks within the dark gray area represent the second protein hydrophobic cavity next to the pyridoquinoxalinic ring of the compounds. Hydrogen atoms, water molecules, ions and counterions are omitted for clarity. The intensity of the surface color for the hydrophobic cavities is proportional to the corresponding strength of ligand/protein interactions.
Our qualitative and quantitative computational analysis confirms the experimental trend in terms of correlation between binding capability and inhibitor activity against the viral polymerase. Indeed, all tested compounds exhibit a good affinity against their target protein in the sub-and low-micromolar range (Table 2) . Moreover, these molecules share a common binding mode, although slight differences are found for compounds B1 and E2, as expected. In fact, from their mapping onto the 3D pharmacophore model it could be anticipated that, at variance with the other ligands, both these compounds would not perfectly map all molecular requirements, although for two opposite reasons. The triazoloquinoline derivative B1, lacking a bulky aromatic substituent on the 5-membered ring, cannot fill the second hydrophobic cavity of the protein binding site; however, it can partially compensate this missing interaction by establishing a further Hbond with the side chain of K263 (Fig. 9A) . On the other hand, the smaller dimensions of the heterocyclic scaffold of imidazopyridine E2 does not allow this compound to assume an optimal conformation in the binding site; consequently E2 cannot perform stable interactions within the first hydrophobic cavity (Fig. 9C) . Conversely, the new imidazoquinoline derivative 6b and the Nbenzylidenequinolinamine F2, featuring a distribution of functional groups similar to D2, fit very well all the pharmacophore requirements (Figs. 9B and D); as a result, their optimal binding conformations reflect into highly favorable DG bind values (Table 2) .
MD results are further corroborated by the quantitative analysis of the H-bonds between the compounds and the polymerase amino acids mainly involved in binding (Table S3) and by a per-residue deconvolution of the enthalpic contribution to binding afforded by each single residue of the BVDV binding site (Fig. 10) . To facilitate reading, the values of DH bind,res for the critical RdRp residues are clustered according to a specific underlying interaction type as follows: A221, I261, I287, and Y289 belong to the first hydrophobic cavity (HC1), and are considered for hydrophobic and pinteractions. Analogously, amino acids V216, Y303, V306, K307, P408, and A412 are clustered in the alternative hydrophobic cavity (HC2), and considered for analogous interaction types.
The collected data support the indications derived from the overall MM/PBSA energetic analysis: the best compounds D2, 6b, and F2 have indeed quite similar interaction spectra as the main Hbonds involving residues R295 and Y674 persist during the entire simulation trajectory, and their contribution to binding amount to the substantial value of À2 kcal/mol for each amino acid (Fig. 10) . Furthermore, the aromatic moiety of the molecules are harbored in both hydrophobic cavities HC1 and HC2; accordingly, the overall corresponding interactions afford an extensive favorable contribution to binding, equal to DH bind,res ¼ À5.95 kcal/mol, -6.00 kcal/ mol, and À5.86 kcal/mol for D2, 6b, and F2, respectively (Fig. 10) . Finally, even the small stabilization afforded by the supplementary H-bond with S411 is confirmed by the energy decomposition analysis.
In this scenario, our computational approach allows to better understand the reasons of the low yet significant inhibitory efficacy of the two remaining compounds B1 and E2. Although the DH bind,res value of the interaction of the triazoloquinoline derivative with the HC2 residues is essentially negligible (À0.12 kcal/mol, Fig. 10 ), the presence of the permanent H-bond, with an Average Dynamic Length (ADL) of 1.99 ± 0.05 Å, detected between the nitro group of B1 and the side chain of K263 partially offsets this contribution; concomitantly, the interactions of B1 with the side chains of residues lining the HC1 are comparable to the ones characterizing the best binder (Fig. 10) . The binding mode of the imidazopyridine E2, instead, satisfies the same requisites underlying the binding of best RdRp inhibitors; however, its smaller scaffold is not able to preserve the same intensity in these interactions, particularly in the case of the hydrophobic contribution from HC1 (DH bind,res ¼ À0.90 kcal/ mol, Fig. 10 ).
The computational results discussed above yielded a precise scheme of the principal intermolecular interactions sustaining the binding between the BVDV RdRp and the present, specific classes of its inhibitors. To validate these indications we next performed a combined in silico/in vitro mutagenesis study of those protein residues involved in the binding site, mainly via highly stabilizing Hbonds with the ligands (Fig. 10) . To this purpose, the following polymerase residues: R195, Y674 (two key ligand/protein anchor points for all tested compounds) and K263 (exerting an exclusive role in the binding mode of the triazoloquinoline derivatives B1) were all mutated into alanine. Then, the affinity of the mutated viral RdRp towards all compounds D2, B1, 6b, E2, and F2 were concurrently evaluated in silico and in vitro. The aggregate results are listed in Table 3 , while all doseeresponse curves obtained from in vitro enzyme assays are showed in Fig. S2 .
Inspection of Table 3 immediately reveals the excellent agreement between computational prediction and experimental determination of IC 50 values for all compounds considered, this evidence thereby constituting a solid validation of the in silico strategy presently adopted. Next, our combined approach was able to dissect the effect of each mutation on the binding strength of all tested compounds against the polymerase, ultimately supporting our description of their binding mode onto the viral protein. In detail, the substitution of the polar residue R295 and Y674 with alanine is predicted to dramatically decrease the BVDV RdRp affinity of all 5 molecules, as testified by the corresponding DDG bind values in Table 3 : the loss of at least 3.5 kcal/mol indeed means that these specific residues are very important not only for their single point interaction but also for the overall conformation and stability of the entire polymerase binding site. Since the exerted effect of the two mutations is comparable for all 5 compounds, for the sake of brevity we will discuss here in details the results achieved for the mutated proteins in complex with the new imidazoquinoline derivatives 6b. The top panel of Fig. S3 nicely shows how the binding site for this compound is deeply affected by both R295A and Y674A mutations: the absence of the relevant drug/protein H-bonds forces the compound to adopt a different conformation upon binding and this, in turn, reflects into a general weakening of the entire network of stabilizing intermolecular interactions.
In keeping, the calculated DG bind values plummet from À8.41 kcal/mol for the wild-type protein to À3.83 kcal/mol and À3.99 kcal/mol for the R295A and Y674A mutant polymerases, respectively (Table 3) . Consistently, the relevant IC 50(calcd) values increase more than 4 orders of magnitude, reaching values as high as 1.6 Â 10 3 mM (R295A) and 1.2 Â 10 3 mM (Y674A). The compound activity tested in vitro parallels this computational prediction: indeed, the BVDV RdRp inhibitory activity of 6b at all compound concentrations considered was so low that the corresponding IC (50,exp) could not be determined (Table 3 and Fig. S2 ). Lastly, the BVDV RdRp K263A mutant protein was studied with the purpose of and validating the specific binding mode predicted for compound B1; as such, lysine residue 263 in fact does not constitute a topic molecular determinant for the polymerase binding of any other compounds considered. In fact, taking again derivative 6b as proof-of-concept, mutating K into A at that position results in a negligible modification of the drug binding configuration and intermolecular interactions (Fig. S3C ) and, hence, in the corresponding DG bind value (Table 3) . On the contrary, for Table 3 In vitro/in silico alanine mutagenesis of the RdRp of BVDV residues K263, R295, and Y674.According to its definition (DDG bind ¼ DG bind(WT) -DG bind(MUT) ), positive values calculated for DDG bind indicate that the considered amino acid substitution at a given position of BVDV RdRp is favorable in terms of interaction with the inhibitors, whereas negative values indicate that the corresponding mutation is unfavorable to binding. n.e. ¼ not evaluable (see Fig. S2 ). Table 3 and Fig. S2 .
Compound

Conclusions
In our long-standing research activity in the design, synthesis, characterization, and testing of antiviral compounds towards viruses of the Flavivirus genera, we produced a plethora of molecular classes among which several compounds were found concomitantly endowed with high potency towards BVDV and negligible toxicity.
Along our antiviral research activity, linear aromatic N-tricyclic systems emerged for their interesting anti-Flaviviridae activity. From the combination of the quinoline nucleus with 1,2,3-triazole, imidazole or pyrazine, best results were obtained for imidazo [4,5- g]quinoline derivatives as anti-BVDV agents. In this paper we expanded the SAR analysis through rational modifications of lead
Diverse substituents at positions R 1 , R 2 , and/or R 3 of proposed model in Fig. 6 , and replacement of phenyl ring with a furane moiety led to 12 new imidazo[4,5-g]quinoline derivatives. Influence on the anti-BVDV activity of the Cl atom at position R 1 , of steric hindrance of substituents in R 2 , of electron donating groups (EDGs) or electron withdrawing groups (EWGs) on the phenyl group (R 3 in Fig. 6 ) and of heterocyclic moiety on quinoline scaffold was evaluated.
The SAR analysis of this molecular series highlighted how the combined presence of a chlorine substituent and an electron withdrawing group such as eCN on position 4 0 of phenyl moiety retains and enhances the antiviral activity of the corresponding derivative compared to the lead compounds C1. From this series, compound 6b emerged as new lead compound, showing EC50 value of 0.3 mM and S.I. > 333.3.
With the purpose of finding a sensible molecular rationale underlying the common affinity towards the RdRp BDVD of these different molecular classes, we then performed a jointed in silico/ in vitro study. To the purpose, we started with the development of a common-feature three-dimensional pharmacophore model, which allowed us to determine two H-bond acceptors and one aromatic hydrophobic feature as the fundamental interactions leading to efficient drug/protein binding. Exploiting this information, the binding site and the binding mode of all 5 classes of compounds onto the BVDV RdRp were retrieved; next, the activity of all compounds was scored using the MM/PBSA approach, obtaining a good agreement between calculated free energies of binding DG bind and the corresponding experimental EC 50 values. The per residue deconvolution of the enthalpic component of DG bind identified two RdRp amino acids e namely R295 and Y674, as the two fundamental H-bond donors, while two hydrophobic cavities HC1 (residues A221, I261, I287, and Y289) and HC2 (residues V216, Y303, V306, K307, P408, and A412) were determined to fulfill the third pharmacophoric requirement. Bases on this information, three RdRp residues critical for drug binding were selected and mutagenized, both in silico and in vitro, into alanine, and the affinity of a set of selected compounds towards the mutant RdRp isoforms was determined accordingly. The agreement between predicted and experimental data confirmed the proposed common molecular rationale shared by molecules characterized by different chemical scaffolds in binding to the BVDV RdRp.
Ultimately, the information yielded by our combined in silico/ in vitro approach could provide an interesting tool for the efficient development of new, powerful compounds against this important Pestivirus.
Experimental section
General directions
Melting points are uncorrected and were measured in open capillaries in a Digital Electrothermal IA9100 melting point apparatus. Table S2 (see Supporting Information).
General procedure for the preparation of imidazo[4,5-g] quinolines 2-5a, 6e11b, 12e13c, and 14b
Following a previously established procedure [23] , compounds 2-5a, 6e11b, 12e13c, and 14b were synthesized by condensation of the diaminoquinolines 1aec (1e3 mmol) with an equimolar amount of the suitable activated aldehyde (Bertagnini's salt), in refluxed ethanol (10e30 mL) for 8 h or in DMF (dimethylformamide) at 130 C for 2e12 h. All Bertagnini's salts were obtained in high yields from the commercially available corresponding aldehydes (Aldrich) with Na 2 S 2 O 5 in ethanol, according to the procedure used by Shriner and Land [29] .
On cooling, a small amount of inorganic compound was filtered off and the ethanol mother liquors were evaporated to dryness in vacuo. The solid residues, colored from orange to dark red, were purified by recrystallization from ethanol in good yields. Compound 4-(4-chloro-3H-imidazo[4,5-g]quinolin-2-yl)benzenesulfonamide (11b) was prepared by condensation of the diaminoquinoline 1b (1.03 mmol) with an equimolar amount of 4-sulfamoylbenzoic and polyphosphoric acid (8.0 g) for 4 h at 200 C. On cooling, the mixture reaction was poured into 100 mL of water and the pH brought to 5 with 10 M NaOH. The resulting precipitate was filtered off and washed with water obtaining 11b in 25% yield. 6. Biology
4-(3H-imidazo
Test compounds
Compounds were dissolved in DMSO at 100 mM and then diluted in culture medium.
Cells and viruses
Cell lines were purchased from American Type Culture Collection ( 
Linear regression analysis
The extent of cell growth/viability and viral multiplication, at each drug concentration tested, were expressed as percentage of untreated controls. Concentrations resulting in 50% inhibition (CC 50 or EC 50 ) were determined by linear regression analysis.
Computational details
Pharmacophore modeling
The purpose of the present work is not using the HipHop derived pharmacophore model tout court for designing new compounds but as a tool for guiding and refining the docking of the selected 31 compounds of all series into the relevant binding site of the BVDV RdRp. Accordingly, four different molecular scaffolds were chosen to ensure a certain degree of structural variety; accordingly, 9 pyridoquinoxalines from series D, 15 imidazoquinolines, of which 5 from series C and 10 new compounds 2-4a, 6e10b, 13c, and 14b, 2 triazolquinolines from series B, and 5 molecules belonging to the E and F series. A principal value (PV) of 2 was assigned to the most active compounds in the training set (EC 50 values <5 mM), whereas PV ¼ 1 was assigned for compounds with the inhibitory activity in the range between 5 mM and 99 mM and PV ¼ 0 was attributed to inactive molecules (EC 50 ! 100 mM, Table S2 ). Compound models energy minimization was performed with the CHARMM forcefield [31] and the classical conformational search was carried out using the Poling algorithm [32] as implemented in the Catalyst module of Discovery Studio [33] . All 23 training set compounds associated with their best conformations were used in the common feature pharmacophore generation using the HipHop feature of Catalyst. As suggested by the inhibitor chemical scaffolds, the hydrogen bond acceptor (HBA), hydrophobic (HY), hydrophobic aromatic (HY_AR), and ring aromatic (RA) features were selected for pharmacophore construction.
The top-ten qualitative pharmacophore models were developed to identify the common features required for efficient BVDV RdRp inhibition, whilst cluster analysis was used to evaluate and categorize differences between composition and spatial location of the chemical features of the models. On the basis of the pharmacophoric features presented, all resulting models could be roughly classified into two major clusters. The first seven models in cluster I identified three functional features, including two HBAs and one HY_AR. The three models in cluster II recognized other functional features, with one HBA, one HY_AR, and one RA. The distances between the pharmacophoric features in cluster I models were rather constant, with little difference in their ranking score; consequently, an analysis of the best fit values of the training set compounds was carried out to determine the best model.
Molecular dynamics simulation
The optimized structures of selected compounds B1, 6b, E2, and F2 were docked into the BVDV RdRp binding pocket using the optimized structure of the RdRp of BVDV taken from our previous work [25, 27, 28] . All docking experiments were performed with Autodock 4.3/AutodockTools 1.4.6 [34] on a win64 platform. The inhibitor/RdRp complex obtained from the docking procedure was further refined in Amber 14 [35] as previously described [25, 27, 28] . Accordingly, the best energy configuration of each complex was subsequently solvated by a cubic box of TIP3P [36] water molecules extending at least 10 Å in each direction from the solute. The system was neutralized and the solution ionic strength was adjusted to the physiological value of 0.15 M by adding the required amounts of Na þ and Cl À ions. Each solvated system was relaxed by 500 steps of steepest descent followed by 500 other conjugate gradient minimization steps and then gradually heated to a target temperature of 300 K. All simulations were carried out with periodic boundary conditions. Subsequently, the density of the system was equilibrated via MD runs in the isothermal isobaric (NPT) ensemble for 50 ps with a time step of 1 fs, with isotropic position scaling and a pressure relaxation time of 1.0 ps? Each system was further equilibrated using NPT MD runs at 300 K, with a pressure relaxation time of 2.0 ps? Three equilibration steps were performed, each 4 ns long and with a time step of 2.0 fs? To check the system stability, the fluctuations of the root-mean-square-deviation (rmsd) of the simulated position of the backbone atoms of the BVDV RdRp protein with respect to those of the initial protein were monitored. All chemicoephysical parameters and rmsd values showed very low fluctuations at the end of the equilibration process, indicating that the systems reached a true equilibrium condition. The equilibration phase was followed by a data production run consisting of50 ns of MD simulations in the canonical (NVT) ensemble. Only the last 20 ns of each equilibrated MD trajectory were considered for statistical data collections. A total of 1000 trajectory snapshots were analyzed the each molecule/polymerase complex.
Free energy of binding analysis
The binding free energy, DG bind , between the selected compounds and the BVDV RdRp was estimated by resorting to the MM/ PBSA [37] approach implemented in Amber 14. According to this well validated methodology [25,27,28,38e40] , the free energy was calculated for each molecular species(complex, protein, and ligand), and the binding free energy was computed as the difference: [41, 42] , and was based on the same snapshots used in the binding free energy calculation.
Computational mutagenesis
For the computational mutagenesis studies, mutation of the selected residues to alanine was performed on the structure of the wild-type BVDV RdRp protein. Each mutated complex was equilibrated in a 0.15 M NaCl TIP3P water solution to relax eventual conformational perturbations induced by mutation of the residue. Each system was then first subjected to 1000 energy minimization steps, followed by further solvent equilibration for100 ps of MDat 300 K. Finally, the entire system was equilibrated for 2 ns at 300 K. The subsequent MD simulation was conducted with Amber 14 as described above.
Pharmacological section
Expression of the BVDV-NS5BD24 polymerase
Expression and purification of the BVDV-NS5BD24 polymerase were performed as described in details in our previous work [25] . In brief, the expression plasmid encoding the His-tagged C-terminal 24-aminoacid-deleted BVDV-NS5B was introduced into the Escherichia coli strain Rosetta™2(DE3)pLysS (Novagene) by chemical transformation. Transformant bacteria were cultured overnight at 30 C in 5 mL of lysogeny broth (LB) supplemented with 25 mg/mL kanamycin and 30 mg/mL chloramphenicol. Cultures were then diluted into 1 L of LB medium additivated by the same quantities of the two antibiotics, and incubated at 30 C until the A600 reached 0.6e0.7. The culture was then induced overnight with 1 mM isopropyl-b-D-thiogalactopyranoside, after which cells were harvested by centrifugation and stored at 80 C until purification.
Purification of NS5B proteins
Cell pellets were thawed and immediately lysed by the addition of 10 mL of CelLytic B (Sigma). Insoluble material was removed by centrifugation at 11,000 rpm for 60 min at 4 C. The soluble extract was applied to a 5-mL column of nickelenitrilotriacetic acideagarose (Qiagen), previously equilibrated with the lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0). The column was washed extensively with the wash buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole, pH 8.0) and the protein was eluted stepwise with the elution buffer containing increasing concentration of imidazole (50 mM NaH 2 PO 4 , 300 mM NaCl, 50e250 mM imidazole, pH 8.0). The polypeptide composition of each column fraction was monitored via Coomassie-stained SDSePAGE analysis. Fractions enriched in pure 6xHis-tagged NS5B protein, recovered in the 130e250 mM imidazole eluates, were pooled and dialyzed against a buffer containing 25 mM TriseHCl, pH7.5, 2.5 mM MgCl 2 , 1 mM dithiothreitol, and 50% glycerol. Protein concentration was determined by the microBradford method (Bio-Rad) using Bovine Serum Albumin (BSA) as standard. Following dialysis, the purified 6xHis-tagged BVDV-NS5BD24 protein was divided into aliquots and stored at À80 C.
